rifapentine (priftin) Report issue

Small molecule Orphan Drug FDA Approved FDA Accelerated Approval FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
PRIFTIN® (rifapentine) is indicated in adults and children 12 years and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis. PRIFTIN must always be used in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. Rifapentine is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. And it acts via the inhibition of DNA-dependent RNA polymerase, leading to a suppression of RNA synthesis and cell death. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency. Rifapentine has shown higher bacteriostatic and bactericidal activities especially against intracellular bacteria growing in human monocyte-derived macrophages.   NCATS

Chemistry

  • SMILES: CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C)C(O)=C4C(O)=C(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N5CCN(CC5)C6CCCC6)=C(O)C4=C3C2=O
  • InChIKey: WDZCUPBHRAEYDL-GZAUEHORSA-N
  • Mol. Mass: 877.0307
  • ALogP: 5.65
  • ChEMBL Molecule:
    rifapentine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$1.7608 - $4.0397
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

25-desacetyl rifapentin | 25-desacetyl rifapentine | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin | 3-(((4-cyclopentyl-1-piperazinyl)imino)methyl)rifamycin sv | cyclopentylrifampicin | dl473 | dl 473 | dl-4-73 | dl 473-it | mdl 473 | mdl-473 | priftin | priftin (tn) | rifapentene | rifapentine | rifapex

Organizations (84)

Research & Development (83)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (2)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (27)

Approved Indications (3)


 

Pruritus

Tuberculosis

Tuberculosis, Pulmonary (approved 1999)

Experimental Indications - Clinical Trial Phases 1-4 (26)


 

Behavior, Addictive (Phase 4)

Brain Injuries, Traumatic (Phase 2)

Diabetes Mellitus (Phase 3)

Drug Interactions (Phase 1)

Drug-Related Side Effects and Adverse Reactions (Phase 1)

Healthy Volunteers (Phase 1)

Hepatitis (Phase 4)

HIV (Phase 4)

HIV Infections (Phase 4)

HIV Seropositivity (Phase 4)

Infertility, Female (Phase 3)

Kidney Failure, Chronic (Phase 4)

Kidney Neoplasms (Phase 4)

Kidney Transplantation (Phase 4)

Latent Tuberculosis (Phase 4)

Mycobacterium avium-intracellulare Infection (Phase 2)

Mycobacterium tuberculosis (Phase 1)

Opioid-Related Disorders (Phase 4)

Patient Compliance (Phase 4)

Pregnancy (Phase 1/Phase 2)

Prostheses and Implants (Phase 3)

Renal Insufficiency (Phase 4)

Silicosis (Phase 3)

Tuberculosis (Phase 4)

Tuberculosis, Female Genital (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial Organizations: 83

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue